AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00763347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-619
Description: SYR-619 50 mg, tablets, orally, once daily for up to 12 weeks.
Study NCT00763347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-619
Description: SYR-619 100 mg, tablets, orally, once daily for up to 12 weeks.
Study NCT00763347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-619
Description: SYR-619 200 mg, tablets, orally, once daily for up to 12 weeks.
Study NCT00763347 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SYR-619 placebo-matching tablets, orally, once daily for up to 12 weeks.
Study NCT00763347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alogliptin
Description: Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
Study NCT01147705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Participants will be given blinded medication and asked to take one tab/day for the first six weeks (100mg strength for two weeks then 300mg strength for four weeks) followed by two tabs/day for the remaining 18 weeks
Study NCT01147705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same appearance/dosing as active drug.
Study NCT02190812 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Forearm supporter
Description: The forearm supporter be use in tennis elbow.
Study NCT02190812 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Grip ball
Study NCT03960476 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PlanYourLifespan.org
Description: The study intervention is a web-based planning tool, PlanYourLifespan.org
Study NCT02782533 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation V3
Study NCT00641407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPL insulin
Description: Starting dose 10 IU bedtime and then titration
Study NCT00641407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: 10 IU bedtime and then titration
Study NCT00418132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide at a dose of 50 mg/day. The dose will be increased to 100 mg/day at Week 2, then to 200 mg/day at Week 4, and finally to 300 mg/day at Week 6.
Study NCT00673140 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Far Infrared Radiation (5μm to 20μm wavelength)
Description: Radiation: Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
Study NCT00673140 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Far infrared radiation
Description: Far infrared radiation at a frequency of 5 microns to 20 microns for 30 to 40 minutes per session.
Study NCT00418132 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo thalidomide
Description: Participants will receive placebo thalidomide. The placebo dose will be increased through to Week 6.
Study NCT03359642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sample
Description: 14 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
Study NCT03359642 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: blood sample
Description: 14 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
Study NCT03359642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stool samples
Description: Study of the fecal microbiota
Study NCT03359642 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stool samples
Description: Study of the fecal microbiota
Study NCT03359642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: food questionnaire
Description: food questionnaire on the seven days before the collection
Study NCT03359642 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: food questionnaire
Description: food questionnaire on the seven days before the collection
Study NCT03359642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: colonoscopy
Description: Only for patients with ulcerative colitis (in routine care)
Study NCT03359642 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: colonoscopy
Description: Only for patients with ulcerative colitis (in routine care)
Study NCT03359642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VOCs profile
Description: Volatile Organic Compounds (VOCs) profile obtained by mass spectrometry
Study NCT03359642 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VOCs profile
Description: Volatile Organic Compounds (VOCs) profile obtained by mass spectrometry
Study NCT03496948 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TeGeCoach
Description: 12-month long telephone health coaching carried out by specially trained coaches. The health coaching is a patient-centered approach based on motivational interviewing, shared decision-making and active listening techniques. Primary care physicians will be constantly involved receiving regular health reports from the coach.~The walking exercise is based on the principle of interval training. Patients will continuously wear an activity monitor device to review their exercise performance and for remote exercise monitoring by the coach. This activity information will be regularly reviewed by the coach to ensure that the patient adheres to the individual walking exercise prescription.
Study NCT01920919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT01920919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02385084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally
Study NCT04119856 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Affiliation with the outgoing lung team
Description: The work of the outgoing lung team takes place in the patient's home and involves the following:~* The outgoing lung team teaches the patients, relatives and primary care staff about symptoms, treatments and instructions related to COPD.~* The patients, relatives and primary care staff can contact the outgoing lung team by telephone day and night.~* The patients report symptoms and measurements to the outgoing lung team using telemedicine as patient reported outcomes.~* The outgoing lung team initiates appropriate treatment by telephone or a home visit. The outgoing lung team always consults a doctor from the Department of Respiratory Diseases and Allergy before initiating treatment.~* The outgoing lung team initiates acute consultations at Department of Respiratory Diseases and Allergy based on patient reported outcomes, home visit or telephone call.
Study NCT00689728 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: LY2127399 will be administered as a single IV infusion over 30 minutes.
Study NCT01340599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Description: Correlative studies
Study NCT01340599 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: immunoenzyme technique
Description: Correlative studies
Study NCT01340599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01340599 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01340599 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo radical prostatectomy
Study NCT01340599 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: therapeutic conventional surgery
Description: Undergo radical prostatectomy
Study NCT01340599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high performance liquid chromatography
Description: Correlative studies
Study NCT01340599 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: high performance liquid chromatography
Description: Correlative studies
Study NCT01340599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mass spectrometry
Description: Correlative studies
Study NCT01340599 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: mass spectrometry
Description: Correlative studies
Study NCT00700505 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FlowPants(R) Garment
Description: The garment is shaped like a pair of boxer briefs. Garment heating is battery-powered.~The garment is activated and begins to heat up 5-15 minutes prior to voiding.
Study NCT00689728 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as a single IV infusion over 30 minutes.
Study NCT05033106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab, Ranibizumab
Description: • A dose of 0.25 mg/0.025 mL ranibizumab (Lucentis) is injected in the right eye of the infant and 0.625 mg/0.025 mL bevacizumab is injected into the vitreous cavity of the left eye 1 mm posterior to the superior/inferior temporal limbus via 30 G needle. The two injections are done sequentially on two consecutive days starting with the eye of more advanced disease.
Study NCT03271905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salbutamol sulfate and ipratropium bromide
Description: Nebulization with salbutamol sulfate and ipratropium bromide during mechanical ventilation.
Study NCT03271905 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mesh nebulization
Description: Nebulization with Mesh device.
Study NCT00306709 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: culturally adapted behavior change
Description: Behavior change strategies which have been modified to include spirituality, AA cultural materials and examples woven into the lesson plans, and sustained peer support.
Study NCT03033264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone
Description: 10 mg of a Dinoprostone vaginal insert.
Study NCT03033264 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double lumen cervical ripening balloon.
Description: Double lumen cervical ripening balloon.
Study NCT02254395 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Study NCT02254395 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep Brain Stimulation
Study NCT00498355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 0.5 mg of ranibizumab by intravitreal injection at baseline and at monthly intervals for the following two months for a total of 3 injections. Afterwards, PRN injections for 9 months.
Study NCT03854383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide mononitrate
Description: Administration of isosorbide mononitrate vaginaly together with misoprostol in induction of labor in postdate women
Study NCT03854383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Used intravaginally to ripe the cevix in induction of labor
Study NCT03854383 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Misoprostol
Description: Used intravaginally to ripe the cevix in induction of labor
Study NCT01623388 — intervention group
Intervention type: PROCEDURE
Intervention: Oral glucose tolerance test for Phase I
Description: Oral glucose tolerance test for Diabetic patients in phase I
Study NCT00435084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APO866
Study NCT00618878 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electroacupuncture
Description: twice a week for 26 treatments in total
Study NCT00618878 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Therapy
Description: twice a week for a total of 26 treatments
Study NCT04071678 — intervention group
Intervention type: BEHAVIORAL
Intervention: Careful examination during endoscopic procedures to identify lesions
Description: When the AI model alarms, check carefully to confirm the lesion
Study NCT02728297 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Staged ETS
Description: Thoracoscopic approach of sympathetic ganglia T3-T12 on one side, retraction of the diaphragm and lung laterally to expose the ganglia then ablation of each ganglion using electrocauterization.
Study NCT04058886 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-delivered Mindfulness
Description: The telephone-delivered mindfulness training intervention that will incorporate the following elements: 1) training for primary caregivers (CG) and their caregiving partner (CP) in a telephone-based mindfulness training intervention; 2) groups of up to eight participants (four CG-CP pairs) plus an instructor, on a shared telephone line; and 3) training in a 8-week, modified MBSR program, which places additional emphasis on training in the following: a) mindful experiencing, including mindfulness of feelings and body sensations; b) mindful communication, including non-verbal mindfulness, mindful listening, and mindful speaking; and c) mindful compassion for self and others. Additionally, homework assignments will involve listening to exercises on a dial-in telephone line; and assignments for CG-CP dyads (e.g. mindful listening and communication practices) as well as CG mindfulness practices in the presence of care recipients (e.g. mindful eating, and mindful listening).
Study NCT01667874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collatamp G sponge
Description: Collatamp G is an antibiotic impregnated sponge
Study NCT02795091 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: manual cleaning
Description: manual clean the rag and floor towel
Study NCT02795091 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: machine clean
Description: machine clean the rag and floor towel
Study NCT04078984 — intervention group
Intervention type: OTHER
Intervention: Experimental
Description: * Daily measures of End Inspiratory Pressure with respiratory synchronisation optimised by use of EAdi~* Daily spontaneous breathing trial using low levels of pressure support~* Pplat, Respiratory System Compliance, Driving Pressure, PEEP, Tidal Volume will be monitored daily as well as clinical and other routine ventilatory data. Data concerning initial severity of ARDS, and duration of ARDS, controlled mechanical ventilation, sedation and neuromuscular blockade and date of first spontaneous breathing trial will be collected. A weaning test will be conducted daily.
Study NCT00609739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Patients will receive CSA therapy beginning on day -3, with a taper commencing on day +60 (unless GVHD) and ending on day +90. For patients >40 kg with normal renal function (creatinine \<1.3 mg/dL), the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children \<40 kg, the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.
Study NCT00609739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 3000 mg/m\^2 intravenously (IV) over 2 hours x 2 (i.e. total 6000 mg/m\^2/day) on days -9 through -4.
Study NCT00609739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Patients with absolute neutrophil count (ANC) \<0.2 x 10\^8/L on day 21 may receive G-CSF at 5 mcg/kg/day. G-CSF will be continued until ANC ≥2.5 x 10\^8/L for two consecutive days. As the malignant cell population of JMML is known to be hypersensitive to GM-CSF, this cytokine will not be given to these patients.
Study NCT00609739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: MTX will be administered to recipients of non-genotypically identical BMT. MTX will be administered at a dose of 15 mg/m\^2 (based on adjusted ideal body weight) intravenously (IV) on day +1 and at a dose of 10 mg/m\^2 IV on days +3, +6, and +11.
Study NCT00609739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Recipients of UCB will receive methylprednisolone 2 mg/kg/day from day +5 to +19 at a dose of 1 mg/kg twice a day (bid) with a 10% taper every week thereafter.
Study NCT00609739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: 10 mg/m\^2 over 30 minutes intravenously (IV) on days -9 through -7.
Study NCT00609739 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: Donor marrow will be collected in the usual sterile manner with a collection goal of 2.0 >10\^8/kg recipient weight. Infused on Day 0.
Study NCT00609739 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation
Description: Umbilical cord blood (UCB) will be cryopreserved prior to transplantation. Cord blood units will be selected for transplantation according to current University of Minnesota Department of Blood and Marrow Transplantation Guidelines.
Study NCT00609739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cis-Retinoic acid
Description: Post-Transplant Cis-Retinoic Acid (CRA) Therapy - CRA will be given at a dosage of 100 mg/m\^2/day by mouth in a single daily dose starting on day +60 and continuing until 1 year after transplant.
Study NCT01142427 — intervention group
Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies
Study NCT01142427 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01772576 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reliance 4-Front lead implantation
Description: The patients selected for participation should be from the investigator's general patient population with an indication for implantation of a single or dual chamber ICD or CRT-D system.
Study NCT03746041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abaloparatide
Description: In cycle 1, patients will be treated with single-agent, subcutaneous (SQ) abaloparatide at a dose of 80 mcg/day for 28 days.
Study NCT03746041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: In cycles 2-4 (each cycle is 28 days), patients will be treated with SQ abaloparatide at a dose of 80 mcg/day and intravenous (IV) bevacizumab 5 mg/kg on days 1 and 15.
Study NCT01978223 — intervention group
Intervention type: PROCEDURE
Intervention: Stool sample collection
Description: Stool samples will be collected from all children enrolled in the study, within 48 hours of admission to the hospital/ ED. Stool samples will be tested to determine the presence or absence of rotavirus (RV). Additionally, for RV-positive cases, the stool samples will be tested to determine the RV genotypes.
Study NCT02999633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form:solution Route of administration: intravenous
Study NCT02999633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Pharmaceutical form:pills Route of administration: oral
Study NCT02999633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Pharmaceutical form:solution Route of administration: intravenous
Study NCT02999633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen
Description: Pharmaceutical form:pills Route of administration: oral
Study NCT02999633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranitidine
Description: Pharmaceutical form:solution Route of administration: intravenous
Study NCT02999633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diphenhydramine
Description: Pharmaceutical form:solution Route of administration: intravenous
Study NCT01032499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytetracycline, taro elixir
Description: comparison of treatment efficacy between oxytetracycline and taro elixir
Study NCT01032499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taro Elixir
Description: Taken orally one tablespoon (15 mL) of Taro Elixir 3 times daily for breakfast, lunch and dinner.
Study NCT04397419 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red Bull Energy Drink
Description: The intervention group receives 250 ml Red Bull Energy Drink 2-3 hours after surgery and 500 ml on postoperative day 1.~Regimen:~* 2-3 hours after surgery: 250 ml~* Postoperative day 1: morning and noon (1-1-0-0) 250 ml
Study NCT04397419 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Still water
Description: The control group receives 250 ml still water 2-3 hours after surgery and 500 ml on postoperative day 1.~Regimen:~* 2-3 hours after surgery: 250 ml~* Postoperative day 1: morning and noon (1-1-0-0) 250 ml
Study NCT00961194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Initial dosage: 250 mg/5 ml~Three doses of ketamine will be tested:~* 0.35 mg/kg~* 0.7 mg/kg~* 1.4 mg/kg Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).~The oral ketamine will be administered in form of syrup.
Study NCT00961194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Initial dosage: 250 mg/5 ml~Three doses of ketamine will be tested:~* 0.35 mg/kg~* 0.7 mg/kg~* 1.4 mg/kg Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).~The oral ketamine will be administered in form of syrup.